Literature DB >> 10496269

Chromosome 17p-linked myasthenias stem from defects in the acetylcholine receptor epsilon-subunit gene.

L Middleton1, K Ohno, K Christodoulou, J Brengman, M Milone, V Neocleous, P Serdaroğlu, F Deymeer, C Ozdemir, A Mubaidin, K Horany, A Al-Shehab, I Mavromatis, I Mylonas, M Tsingis, E Zamba, M Pantzaris, K Kyriallis, A G Engel.   

Abstract

OBJECTIVE: To identify and to characterize functionally the mutational basis of congenital myasthenic syndromes (CMS) linked to chromosome 17p.
BACKGROUND: A total of 37 patients belonging to 13 CMS families, 9 of them consanguineous, were investigated. All patients were linked previously to the telomeric region of chromosome 17p. Two candidate genes in this region encode synaptobrevin 2, a presynaptic protein, and the epsilon-subunit of the acetylcholine receptor (AChR). Direct sequencing of the synaptobrevin 2 gene revealed no mutations. The authors thus searched for mutations in the epsilon-subunit gene of AChR.
METHODS: Direct sequencing of the AChR epsilon-subunit, restriction analysis, allele-specific PCR, and expression studies in human embryonic kidney cells were performed.
RESULTS: The authors identified two previously characterized and five novel epsilon-subunit gene mutations, all homozygous, in the 13 kinships. Two of the novel mutations are truncating (epsilon723delC and epsilon760ins8), one is a missense mutation in the signal peptide region (epsilonV-13D), one is a missense mutation in the N-terminal extracellular domain (epsilonT51P), and one is a splice donor site mutation in intron 10 (epsilonIVS10+2T-->G). Unaffected family members have no mutations or are heterozygous. Expression studies indicate that the four novel mutations in the coding region of the gene and the most likely transcript of the splice-site mutation, which skips exon 10, are low-expressor or null mutations.
CONCLUSIONS: Chromosome 17p-linked congenital myasthenic syndromes are caused by low-expressor/null mutations in the AChR epsilon-subunit gene. Mutations in this gene are a common cause of CMS in eastern Mediterranean countries.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496269     DOI: 10.1212/wnl.53.5.1076

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  A retrospective review of 15 patients with familial myasthenia gravis over a period of 25 years.

Authors:  Hui-Yu Feng; Wei-Bin Liu; Chuan-Ming Luo; Li-Xuan Yang; Wei Fang; Li Qiu; Xin Huang; Yan Li; Ru-Xun Huang
Journal:  Neurol Sci       Date:  2011-11-05       Impact factor: 3.307

Review 2.  Current status of the congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-11-21       Impact factor: 4.296

3.  Mutation causing congenital myasthenia reveals acetylcholine receptor beta/delta subunit interaction essential for assembly.

Authors:  P A Quiram; K Ohno; M Milone; M C Patterson; N J Pruitt; J M Brengman; S M Sine; A G Engel
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 4.  Congenital myasthenic syndromes: genetic defects of the neuromuscular junction.

Authors:  Kinji Ohno; Andrew G Engel
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

5.  Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up.

Authors:  Hacer Durmus; Xin-Ming Shen; Piraye Serdaroglu-Oflazer; Bulent Kara; Yesim Parman-Gulsen; Coskun Ozdemir; Joan Brengman; Feza Deymeer; Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2017-11-28       Impact factor: 4.296

Review 6.  The therapy of congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 7.  Therapeutic strategies in congenital myasthenic syndromes.

Authors:  Ulrike Schara; Hanns Lochmüller
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 8.  The spectrum of congenital myasthenic syndromes.

Authors:  Andrew G Engel; Kinji Ohno; Steven M Sine
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.